|
Steady Dividend And Pipeline Pivots Are Starting To Pay Off For This Biopharma |
|
|
Hello and welcome to Everyday Alpha, the daily newsletter showcasing a different stock opportunity every day the market is open. We give you laser-focused content to save you time and energy so you can make educated investment decisions quickly. |
|
|
|
|
|
AbbVie Inc. | | July 1 – Pre‑market
Ticker: ABBV | Sector: Biopharmaceuticals | Market Cap: ~$322B |
|
|
|
30‑Second Take |
Why now? AbbVie is coming off a rough quarter, down 11%, but the long-term story looks increasingly attractive. |
The company's high-yield dividend remains a cornerstone, while its transition away from Humira is finally gaining traction. |
Skyrizi and Rinvoq are delivering double-digit growth, and the recent $10B Elahere acquisition could become a multi-billion-dollar oncology franchise. |
Despite regulatory noise and patent cliffs, AbbVie continues to post solid revisions, raise its dividend, and execute on its post-Humira game plan. |
After a healthy pullback, the risk-reward profile looks favorable heading into Q2 earnings. |
|
Next Big Move (Sponsored) | | | The secret to finding big moves that could end up like the ones below is knowing where to look: | Triller Group Inc (ILLR): From $.66 to $8.86 (+1,242%) Quantum Computing Inc (QUBT): From $.35 to $4.69 (+1,240%) Eco Wave Power (WAVE): From $1.01 to $12.39 (+1,126%)
| The choice is yours: You can do nothing, and you'll end up on the sidelines for the next +1,200% move. Or you can take action… |
Not long from now, Market Pulse Today will reveal its first alert of the quarter—a company with serious breakout potential.
| The best part? | It's 100% free. | You can make it happen or wonder "What happened?" | [Click Here to Get the Alert First]
(By clicking any of the links above, you will get this free report and a free subscription to Market Pulse Today's daily email newsletter. You are also agreeing to the terms of the privacy policy. Unsubscribe at any time.) |
|
|
|
Trade Setup |
Time frame: Medium-term income and capital appreciation
Edge type: Dividend consistency plus pipeline unlocks |
|
Snapshot Table |
Metric | Value | Current Stance |
|---|
Price | $185.67 | Mid-range |
|---|
52‑week range | $163.52 – $218.66 | Below recent highs |
|---|
Short interest | ~0.84% | Low |
|---|
Next catalyst | Q2 earnings (Jul 23–28, 2025) | |
|---|
|
|
Chart |
|
5-Day Synopsis: ABBV closed down 2.4% on Friday last week, but rebounded in after-hours trading slightly. |
The selloff followed a three-day uptick and likely reflected quarter-end positioning rather than a change in narrative. |
Volume surged to nearly 4x the average, suggesting institutional rotation. Key support near $180 held, and short-term momentum remains intact. |
|
Bull Case |
Core thesis: AbbVie is showing that it can execute a post-blockbuster pivot while continuing to deliver on shareholder return. |
With 53 straight years of dividend hikes and a forward yield of 3.6%, the stock appeals to income-focused investors. |
The growth narrative is now taking shape. Skyrizi and Rinvoq are scaling fast and are projected to fully replace Humira revenue by 2027. |
Both drugs are expanding into new indications, strengthening AbbVie's immunology moat. |
In oncology, the recent $10.1 billion acquisition of ImmunoGen puts AbbVie in full control of Elahere, a treatment for ovarian cancer projected to reach $6 billion in annual sales by 2034. |
AbbVie holds 100% of the current Elahere market and is positioned to dominate one of the highest-growth oncology segments in the decade ahead. |
Meanwhile, earnings momentum is quietly building. Six analysts have upgraded FY2025 EPS estimates in the past 60 days, lifting the consensus to $12.28 per share. |
ABBV has also delivered a positive earnings surprise in each of the past four quarters. |
Catalysts: |
Catalysts for ABBV include: |
Q2 earnings report expected July 23–28 Skyrizi and Rinvoq growth updates Elahere clinical expansion Dividend ex-date: July 15 Drug pricing legislation and tariff clarity ahead of the election cycle
|
Valuation upside: ABBV trades at a forward P/E of ~14.8, well below historical pharma averages, and less than half the multiple of many peers. |
It also offers 5.7% free cash flow yield and a strong track record of capital returns. |
Wall Street's average 12-month price target is $208.86, about 14.5% upside from current levels, and that's before layering in 3.6% yield. |
If pipeline momentum continues and policy overhangs clear, ABBV could re-rate back toward $210–215 in the second half. |
Technical tailwind: The stock is hovering just above its 100-day moving average. RSI is neutral, and momentum remains constructive with bids building above $180. |
A clean breakout above $190 would signal confirmation and open the door for a move back to the $200 range. |
|
Quiet Breakouts (Sponsored) | | | You can keep scrambling to make sense of this chaotic market… or you can take 10 seconds and shortcut the noise. | This free report reveals one little-known company we believe could be the next big mover in 2025 — and it's part of a broader set of rapid-fire alerts we send out regularly. | We don't waste time on hype. We focus on stocks with the potential to deliver 6-month upside most investors only dream of. | Take Candel Therapeutics (CADL), for example — it ran from $0.66 to over $14 in just a few months. | Opportunities like that are rare — but missing them is even worse. | That's why we created Stock News Trends: to surface names before the crowd. | Click here to get the next report free — and you'll be first in line for alerts that most investors never see. | (By clicking any of the links above, you will get this free report and a free subscription to Stock News Trend's daily email newsletter. You are also agreeing to the terms of the privacy policy. Unsubscribe at any time.) |
|
|
|
Bear Case |
Key risk: AbbVie's transition away from Humira has been well-telegraphed, but the financial aftershocks continue. |
In Q2 2025, the U.S. market will have been open to Humira biosimilars for over a year. While Rinvoq and Skyrizi are growing, they haven't fully offset the revenue gap. |
Top-line growth remains tepid, and much of AbbVie's recent earnings strength has come from cost controls rather than revenue acceleration. |
If the company fails to meet its own expectations for immunology growth, or if biosimilar erosion extends to other legacy assets, investors may question the pace and credibility of the recovery. |
Pipeline dependence: The Elahere story has grabbed headlines, but AbbVie's oncology pipeline remains in its early stages outside that asset. |
Elahere itself, while promising, is a single-product platform operating in a highly competitive space with new entrants, regulatory scrutiny, and a narrow focus on indications. |
If adverse events emerge or reimbursement challenges slow adoption, Elahere's expected $6B market potential may not materialize. |
Beyond that, AbbVie lacks a blockbuster-level drug in late-stage development, which could limit visibility beyond 2026–2027. |
The ImmunoGen acquisition was expensive, and any misstep in execution could amplify valuation concerns. |
Regulatory and policy headwinds: Drug pricing is once again in political crosshairs. |
AbbVie's portfolio is heavily skewed toward biologics and specialty meds, exactly the type of therapies most likely to face pricing caps under a future "most favored nation" model. |
Tariffs on imported ingredients, especially from Asia, could pressure COGS, and any movement on Medicare negotiation expansion could reduce margin headroom. |
With a highly politicized backdrop heading into the 2026 midterms, regulatory noise is likely to rise, particularly for pharmaceutical firms with significant Medicare exposure. |
Valuation risk and accounting distortion: ABBV trades at over 78x trailing earnings, largely due to amortization drag from the Allergan acquisition. |
This creates optics problems: even though forward P/E is more reasonable (~14.8x), headlines may mischaracterize ABBV as "expensive." |
Combined with slowing EPS growth and below-peer ROIC, the result could be multiple compression, especially if bond yields continue rising, putting pressure on defensive, dividend-heavy names. |
Sentiment fragility: ABBV is a dividend king, but it's not a momentum favorite. |
The stock has underperformed the S&P 500 in three of the past five years and continues to lag peers like Eli Lilly and Novo Nordisk, which are seen as more innovation-driven. |
The 10% post-2023 return masks a choppy narrative. |
ABBV's investor base is mostly income-oriented, but even that support could weaken if margin pressure or pipeline stumbles cause EPS or dividend growth to stall. |
If Q2 earnings disappoint, or if Elahere fails to show traction, ABBV could lose support from both growth and income investors, keeping it trapped in a $175–$190 range through the back half of 2025. |
|
Quick Checklist |
✅ Dividend support adds cushion at current levels
✅ Q2 earnings in focus with pipeline momentum key
✅ Sentiment may shift if management guides above consensus
|
|
Deep‑Dive Links |
|
|
That's all for today's Everyday Alpha. We'll have a new pick for you every morning before the market opens, so stay tuned! |
Best Regards,
—Noah Zelvis
Everyday Alpha |
